Allogene Therapeutics

OverviewSuggest Edit

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer. The Company's portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T therapy candidate currently in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

TypePublic
Founded2018
HQSouth San Francisco, CA, US
Websiteallogene.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Feb 2020)205(+8%)
Job Openings40
Share Price (Nov 2021)$19.3
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Allogene Therapeutics

Arie Belldegrun

Arie Belldegrun

Executive Chairman and Co-Founder
David Chang

David Chang

President, Chief Executive Officer and Co-Founder, Director
David Bonderman

David Bonderman

Chairman And Founding Partner
Alison Moore

Alison Moore

Chief Technical Officer
Barbra Sasu

Barbra Sasu

Chief Scientific Officer
Debbie Messemer

Debbie Messemer

Board Member
Show more

Allogene Therapeutics Office Locations

Allogene Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
210 E Grand Ave
Show all (1)

Allogene Therapeutics Financials and Metrics

Allogene Therapeutics Revenue

USD

Revenue (Q1, 2021)

38.3m

Net income (Q1, 2021)

(33.0m)

EBIT (Q1, 2021)

(33.2m)

Market capitalization (12-Nov-2021)

2.7b

Closing stock price (12-Nov-2021)

19.3

Cash (31-Mar-2021)

236.9m

EV

2.6b
Allogene Therapeutics's current market capitalization is $2.7 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

2.0k41.0m57.5m65.3m

R&D expense

151.9m144.5m193.0m

Operating expense total

2.0k192.8m202.0m258.2m

EBIT

(2.0k)(192.8m)(202.0m)(258.2m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

38.3m

General and administrative expense

2.6m12.5m11.3m13.1m14.2m15.0m15.6m15.9m16.6m16.4m

R&D expense

122.5m10.9m23.4m31.8m40.0m42.0m47.3m51.4m55.2m

Operating expense total

2.6m135.0m22.2m36.5m46.0m55.0m57.7m63.2m68.0m71.5m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

92.4m175.1m183.4m

Prepaid Expenses

17.2m

Current Assets

468.0m544.6m845.1m

PP&E

8.6m56.4m118.8m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.0k)(211.5m)(184.6m)(250.2m)

Depreciation and Amortization

1.5m5.0m7.6m

Accounts Payable

8.8m(985.0k)615.0k

Cash From Operating Activities

(44.7m)(137.3m)(115.1m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(2.6m)(137.5m)(181.0m)(31.6m)(72.8m)(123.6m)(54.5m)(115.5m)(181.7m)(33.0m)

Depreciation and Amortization

450.0k953.0k695.0k1.8m3.2m2.0m3.9m5.7m1.9m

Accounts Payable

1.3m3.1m(348.0k)1.3m(3.1m)(1.0m)(503.0k)1.7m4.2m

Cash From Operating Activities

5.0k(6.0m)(23.2m)(30.3m)(55.1m)(87.1m)(40.8m)(67.5m)(105.1m)(49.3m)
Show all financial metrics

Allogene Therapeutics Operating Metrics

Sep, 2018FY, 2018FY, 2019

Patients Included in Clinical Trials

182121

Pre-Clinical Phase Products

778

Phase I Trials Products

114

Office and Laboratory Space, square feet

89.54 k222.49 k200.94 k
Show all operating metrics

Allogene Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Allogene Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Allogene Therapeutics Online and Social Media Presence

Embed Graph

Allogene Therapeutics News and Updates

Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that it will present updated data from its blood cancer…

Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2021 financial resul…

Allogene Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

Thinking about buying stock in Farmmi, Tata Motors, Grom Social Enterprises, Allogene Therapeutics, or Paltalk?

NEW YORK, Oct. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, TTM, GROM, ALLO, and PALT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

: Allogene Therapeutics stock drops as much as 40% as FDA puts hold on cancer drug study

Allogene Therapeutics Inc. ALLO shares plunged in the extended session Thursday after the biotech drug developer said the Food and Drug Administration placed a hold on the company’s cancer drug clinical trials. Allogene shares, which had closed up 1.7% at $24.38 in the regular session, plunged as mu…

Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Jae Park, M.D., acting Chief of Ce…
Show more

Allogene Therapeutics Blogs

Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update

New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial

Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to Therapy Investigation Ongoing to Further Characterize the Finding, Including Any Clinical Relevance, Evidence of Clonal

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

Allogene Therapeutics Reports Second Quarter 2021 Financial Results Content Import Wed, 08/04/2021 - 16:05 Allogene Therapeutics Reports Second Quarter 2021 Financial Results Aug 4, 2021 at 4:02 PM EDT This release is a backfill from a News Wire …

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer Maricel.Felici… Mon, 06/21/2021 - 07:01 Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer Jun 21, 2021 at 7:00 AM EDT This release is a backfill from a News Wir…

Allogene Therapeutics Reports First Quarter 2021 Financial Results

CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Longer Term Follow-Up from the ALPHA Study and Consolidation Dosing in Both ALPHA and ALPHA2 Study to be Included Allogene to Host

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Content Import Thu, 02/25/2021 - 16:04 Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Feb 25, 2021 at 4:02 PM EST …
Show more

Allogene Therapeutics Frequently Asked Questions

  • When was Allogene Therapeutics founded?

    Allogene Therapeutics was founded in 2018.

  • Who are Allogene Therapeutics key executives?

    Allogene Therapeutics's key executives are Arie Belldegrun, David Chang and David Bonderman.

  • How many employees does Allogene Therapeutics have?

    Allogene Therapeutics has 205 employees.

  • Who are Allogene Therapeutics competitors?

    Competitors of Allogene Therapeutics include Novartis, Amgen and Bellicum Pharmaceuticals.

  • Where is Allogene Therapeutics headquarters?

    Allogene Therapeutics headquarters is located at 210 E Grand Ave, South San Francisco.

  • Where are Allogene Therapeutics offices?

    Allogene Therapeutics has an office in South San Francisco.

  • How many offices does Allogene Therapeutics have?

    Allogene Therapeutics has 1 office.